XR Beta 50 Tablet contains Metoprolol Succinate 50mg, a cardioselective beta-1 adrenergic receptor blocker indicated for the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in cardiac tissue, Metoprolol Succinate decreases heart rate, myocardial contractility, and cardiac output, thereby reducing oxygen demand and lowering blood pressure. The extended-release formulation ensures a consistent plasma concentration, allowing once-daily dosing and improved patient compliance. XR Beta 50 is particularly beneficial in patients with a history of myocardial infarction to reduce mortality and risk of subsequent cardiac events. It is contraindicated in patients with severe bradycardia, cardiogenic shock, and overt cardiac failure. Caution is advised in patients with asthma, diabetes, and peripheral vascular disease. Common adverse effects include fatigue, dizziness, and gastrointestinal disturbances. Dose adjustments may be necessary in hepatic impairment. XR Beta 50 should be discontinued gradually to avoid acute tachycardia, hypertension, or ischemia. Regular monitoring of blood pressure, heart rate, and clinical status is recommended during therapy. This medication should be used under medical supervision, with adherence to prescribed dosing to optimize therapeutic outcomes and minimize adverse effects.